SNSE News and Press, Sensei Biotherapeutics Inc. From 11/21/22

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it has entered into a Sponsored Research Agreement with Washington ...

Calls for the Board to take immediate action to regain the trust of the shareholders Best path forward for Sensei would be to return cash to shareholders Encourages all other shareholders to reach out to the Board directly to express their views SLIEMA, Malta, ...

The following slide deck was published by Sensei Biotherapeutics, Inc. in conjunction with this event. For further details see: Sensei Biotherapeutics (SNSE) Investor Presentation -Slideshow

- SNS-101, a highly pH-selective antibody to VISTA, demonstrated anti-tumor effects and promising pharmacokinetic properties in preclinical studies - - Characterization of endogenous expression patterns, and identification of novel T-cell receptors, of VSIG4 enables advancement ...

Sensei Biotherapeutics press release ( NASDAQ: SNSE ): Q3 GAAP EPS of -$0.44 misses by $0.09 . Cash, equivalents and marketable securities were $116.6 million as of September 30, 2022, as compared to $147.6 million as of December 31, 2021. Sensei expects its current ca...

- Recent SNS-101 preclinical data demonstrate a favorable pharmacokinetic profile, evidence of advanced anti-tumor effects and a superior cytokine release profile - - New preclinical data on multiple programs to be presented at the Society for Immunotherapy of Cancer...

Featuring Dr. Robert Schreiber, globally recognized expert on the immune system’s role in anti-cancer immunity Pre-registration available for live event, to be held November 21, 2022, at 2:15 p.m. ET BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeuti...

BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer, will present at the...

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present two posters at the Society for Immunotherapy of Cancer (SITC...

- SNS-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-PD-1 antibodies and a significantly improved cytokine release profile as compared to a pH-independent VISTA antibody BOSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Sensei B...